The limited impact of Ozempic on the U.S. obesity epidemic
The term ‘obesity’ elicits a range of interpretations. Some view it as merely another way to describe excess weight, while others perceive it as a derogatory label for larger body sizes. Still, some consider it a reflection of personal failings, such as a lack of discipline or willpower. However, for over a decade, the medical field has acknowledged obesity as a chronic health condition, akin to diseases like cancer, diabetes, and hypertension. This disease significantly elevates the risk of severe COVID-19 outcomes, is connected to numerous health complications, and is responsible for approximately 4 million preventable deaths annually. Moreover, obesity manifests in various forms, with diverse origins, clinical signs, and treatment responses.
The surge in popularity of GLP-1 medications such as Ozempic, Wegovy, and Mounjaro has somewhat simplified this complex issue. These drugs are often hailed as the ultimate solution to obesity, a perspective that overlooks the multifaceted nature of the condition. Unfortunately, Ozempic alone cannot address America’s obesity crisis. Obesity extends beyond mere physical inactivity or excessive eating. It’s influenced by a range of factors including genetic predispositions, mental health, socio-economic conditions, and environmental factors.
In clinical settings, the variation in obesity cases is significant. For instance, a mutation in the MC4R gene is associated with an 18% increased likelihood of obesity, while certain antipsychotic medications can lead to substantial weight gain. Although GLP-1 medications can be beneficial, they primarily address hormonal imbalances and do not tackle other contributing factors. This reductionist approach is also evident in the use of Body Mass Index (BMI) to diagnose obesity. BMI, initially designed for white European males, often inaccurately represents obesity levels in different ethnic groups, leading the American Medical Association to advise against its sole use. Currently, a global commission of experts is redefining obesity, moving away from height and weight measurements to focus on specific symptoms and signs.
The response to treatment among patients with obesity also varies greatly. For example, the GLP-1 drug Wegovy showed an average body weight reduction of 16% in a study, yet individual results ranged widely. This underscores the need for personalised treatment plans rather than a singular drug-based approach. However, the U.S. healthcare system faces significant challenges in this regard. With only a small number of physicians specialised in obesity treatment and federal restrictions on covering obesity medications, only a fraction of those who could benefit from such treatments receive them. Instead, many are advised to simply eat less and exercise more, a strategy that overlooks the complexity of obesity.
Effective obesity treatment involves a multidisciplinary approach, combining diet, exercise, behavioural therapy, medication, and sometimes surgery. Unfortunately, the scarcity of specialised physicians and the prevalence of misleading diet products and scams exacerbate the issue. The U.S. weight loss market, valued at $160 billion in 2023, is a testament to this. Moreover, misconceptions about GLP-1 medications, such as the idea that they are a cure-all for obesity, lead to unrealistic expectations and criticisms. Like insulin or hypertension treatments, discontinuing GLP-1 drugs can result in a reversal of their effects, a fact that should be recognised rather than criticised.
Addressing obesity, which costs the U.S. around $1.7 trillion annually, requires acknowledging the progress made with GLP-1 drugs while also understanding their limitations. A holistic, patient-centred, and empathetic approach to obesity treatment is essential. This approach should not only address the unique needs and circumstances of each individual but also aim to improve overall health and well-being. While medications like Ozempic, Wegovy, and Mounjaro offer significant potential, they are not the all-encompassing solution often portrayed in the media. A broader, more nuanced understanding and response to obesity is crucial for effective management and treatment.
Read More
CDC reports nearly half of US states have over 35% of adults living with obesity
Obesity continues to extend its grasp across an increasing number of states in the US, as recent data from the Centers for Disease Control and Prevention (CDC) underscores. According to the fresh batch of information, as of 2022, a minimum of 35% of the adult population in 22 states was categorised as having obesity. This signifies a growth from the 19 states documented in 2021.
Drawing a comparison to a decade prior, the CDC highlighted that no state had reported an adult obesity prevalence of 35% or above, underlining a troubling upward trajectory.
This data has been gleaned from the Behavioral Risk Factor Surveillance System, a meticulously conducted interview survey collaboratively administered by the CDC along with state health departments. The criteria for obesity was a Body Mass Index (BMI) of 30 or above, as ascertained through the survey.
Three states bore the brunt of obesity with more than 40% of their adult populace having obesity—Louisiana, Oklahoma, and West Virginia. The list further includes Alabama, Arkansas, Delaware, Georgia, Indiana, Iowa, Kansas, Kentucky, Mississippi, Missouri, Nebraska, North Dakota, Ohio, South Carolina, South Dakota, Tennessee, Texas, Virginia, and Wisconsin, all having an obesity prevalence of at least 35% among adults.
An in-depth examination of the 2022 Adult Obesity Prevalence Maps divulges certain demographic groups being disproportionately affected by obesity, with discernible discrepancies across racial and ethnic lines.
The data revealed that a minimum of 35% of American Indian or Alaska Native adults had obesity in 33 states, alongside black adults in 38 states, Hispanic adults in 32 states, while the corresponding figure for white adults stood at 14 states. Notably, the obesity rates among Asian adults did not cross the 35% threshold in any state.
Karen Hacker, MD, MPH, who helms the CDC’s National Center for Chronic Disease Prevention and Health Promotion, articulated the dire need for enhanced support directed towards obesity prevention and treatment, terming it an “urgent priority”. She elaborated on the multifaceted nature of obesity, being influenced by a gamut of factors including dietary habits, physical activity levels, sleep patterns, genetic factors, and certain medications.
Dr. Hacker emphasised that the solution doesn’t adhere to a one-size-fits-all approach, but acknowledged the effectiveness of certain key strategies like addressing core social determinants of health. These include better access to healthcare, the availability of healthy and affordable food, and safe venues for engaging in physical activity.
The CDC’s 2022 maps accentuate the necessity for population-centric interventions to ensure universal access to healthy foods, safe exercising environments, stigma-free obesity prevention and treatment initiatives, alongside evidence-backed healthcare services encompassing medication and surgery.
The repercussions of obesity extend beyond the societal stigma, with individuals suffering from obesity being at an escalated risk for severe health conditions like heart disease, stroke, Type 2 diabetes, certain types of cancer, deteriorated mental health, and aggravated repercussions from COVID-19, as per CDC’s observations.
In a bid to combat this escalating obesity epidemic, the CDC’s Division of Nutrition, Physical Activity, and Obesity is propelling a slew of proven strategies at the state and local levels. These strategies encompass making physical activity safer and more accessible, facilitating healthier food choices, promoting breastfeeding, fortifying obesity prevention standards in early care and education settings, and augmenting the availability and access to family healthy weight programs.
The CDC has been vociferous in endorsing supportive environments for healthy eating and active lifestyles across various settings. Among the suggested preventative strategies are increased consumption of fruits and vegetables, encouraging breastfeeding, embracing physical activity, averting sedentary lifestyles, and minimising screen time, all of which are projected to play a vital role in reversing the obesity trend sweeping the nation.
Read More